StockData
Cadrenal Therapeutics, Inc. logo

Cadrenal Therapeutics, Inc. (CVKD) stock

CVKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/30
$1.88+0.48 (+34.29%)

Close on Nov 17, 2026Market cap $6.71MP/E –Yield 877.66%

Cadrenal Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Cadrenal Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.83M, down 44.1% year over year. For fiscal 2025 it was $4.10M, down 2.5% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.10M-2.5%
FY2024Dec 31, 2024$4.21M+3.0%
FY2023Dec 31, 2023$4.08M+1940.7%
FY2008Mar 31, 2008$200.00K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$705.15K-34.6%
Q1 FY2026Mar 31, 2026$771.51K-53.7%
Q4 FY2025Dec 31, 2025$666.32K-56.7%
Q3 FY2025Sep 30, 2025$688.47K-12.3%
Q2 FY2025Jun 30, 2025$1.08M-14.1%
Q1 FY2025Mar 31, 2025$1.67M+165.2%
Q4 FY2024Dec 31, 2024$1.54M+325.8%
Q3 FY2024Sep 30, 2024$784.65K-75.7%
Q2 FY2024Jun 30, 2024$1.25M–
Q1 FY2024Mar 31, 2024$629.03K–
Q4 FY2023Dec 31, 2023$361.13K–
Q1 FY2023Mar 31, 2023$3.24M–

More Cadrenal Therapeutics figures

See a number that looks wrong?